NEW
Products & Technologies
JDI and CyteSi Agree to Develop and Manufacture EWOD-based Backplanes for Biological Processing Units (BPUs)
0
JDI has entered into a Memorandum of Understanding (MOU) with CyteSi, Inc., a U.S.-based company developing Biological Processing Units (BPUs), devices that automatically manipulate and process biological samples through electrical action in the bio-medical field. JDI will develop and manufacture backplanes for the BPUs.
- EWOD (Electro-Wetting on Dielectric): A technology that uses voltage to control tiny droplets and enable digital microfluidics
- BPU (Biological Processing Unit): A device that handles and processes small amounts of biological samples using EWOD technology
1. Driving Innovation in BPU Technology with CyteSi Products and Its Significance to JDI
JDI’s EWOD backplanes are used in combination with devices developed by CyteSi. These innovative BPU systems enable biological processes, such as mixing, separation, and reaction, to be carried out on a chip through precise electrical control of tiny droplets. To achieve this high level of stable droplet control, JDI’s advanced microfabrication technology on glass substrates is used.
These technologies are expected to significantly reduce validation and testing time, which have traditionally been labor-intensive. They also improve efficiency, reduce labor requirements, and lower reagent costs across a wide range of applications, including drug discovery, next-generation sequencing, and clinical diagnostics in the medical field.
Against the backdrop of these technological innovations, this field is expected to grow alongside the advancement of automation and digitalization in the life sciences sector, and JDI positions it as a new revenue opportunity in its non-display business.
2. Overview of the MOU and Production Plan
JDI has entered into a Memorandum of Understanding (MOU) with CyteSi to further strengthen their partnership to collaborate on technology related to CyteSi’s BPU development and JDI’s EWOD backplanes.
JDI plans to commence mass production and supply of the backplanes within 2026.
(JDI Booth Location: West Hall 3, A-08)
URL：JDI to Exhibit at “Smart Sensing 2026” | News Releases | News | Japan Display Inc.
About CyteSi, Inc.
CyteSi, Inc., founded in 2018 and headquartered in California, USA, develops Biological Processing Units (BPUs).
Its BPUs utilize digital microfluidics technology and AI to digitize and automate biological experiments. By transforming labor-intensive validation and testing processes into software-controlled workflows, and enabling precise droplet control using micro-electrodes, these solutions help accelerate experimentation, reduce labor requirements, and improve reproducibility.
CyteSi Website: https://www.cytesi.com/
Contact: https://www.webcoms.jp/jdi/eng/form.php
– Enabling Next-Generation Bio Processing Through Highly Precise Droplet Control Using TFT Technology –
JDI has entered into a Memorandum of Understanding (MOU) with CyteSi, Inc., a U.S.-based company developing Biological Processing Units (BPUs), devices that automatically manipulate and process biological samples through electrical action in the bio-medical field. JDI will develop and manufacture backplanes for the BPUs.
(Source: CyteSi, Inc.)
- EWOD (Electro-Wetting on Dielectric): A technology that uses voltage to control tiny droplets and enable digital microfluidics
- BPU (Biological Processing Unit): A device that handles and processes small amounts of biological samples using EWOD technology
1. Driving Innovation in BPU Technology with CyteSi Products and Its Significance to JDI
JDI’s EWOD backplanes are used in combination with devices developed by CyteSi. These innovative BPU systems enable biological processes, such as mixing, separation, and reaction, to be carried out on a chip through precise electrical control of tiny droplets. To achieve this high level of stable droplet control, JDI’s advanced microfabrication technology on glass substrates is used.
These technologies are expected to significantly reduce validation and testing time, which have traditionally been labor-intensive. They also improve efficiency, reduce labor requirements, and lower reagent costs across a wide range of applications, including drug discovery, next-generation sequencing, and clinical diagnostics in the medical field.
Against the backdrop of these technological innovations, this field is expected to grow alongside the advancement of automation and digitalization in the life sciences sector, and JDI positions it as a new revenue opportunity in its non-display business.
2. Overview of the MOU and Production Plan
JDI has entered into a Memorandum of Understanding (MOU) with CyteSi to further strengthen their partnership to collaborate on technology related to CyteSi’s BPU development and JDI’s EWOD backplanes.
JDI plans to commence mass production and supply of the backplanes within 2026.
(JDI Booth Location: West Hall 3, A-08)
URL：JDI to Exhibit at “Smart Sensing 2026” | News Releases | News | Japan Display Inc.
About CyteSi, Inc.
CyteSi, Inc., founded in 2018 and headquartered in California, USA, develops Biological Processing Units (BPUs).
Its BPUs utilize digital microfluidics technology and AI to digitize and automate biological experiments. By transforming labor-intensive validation and testing processes into software-controlled workflows, and enabling precise droplet control using micro-electrodes, these solutions help accelerate experimentation, reduce labor requirements, and improve reproducibility.
CyteSi Website: https://www.cytesi.com/
Contact: https://www.webcoms.jp/jdi/eng/form.php